
Loading, please wait...

Loading, please wait...

In a survey of 1,254 patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors, the most used agents were dalpiciclib and abemaciclib. Over 81% experienced adverse events (AEs), with leukopenia and neutropenia being most common. Differences in safety and symptom burden among CDK4/6 inhibitors underscore the need for personalized treatment selection to optimize patient outcomes and well-being.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


In a survey of 1,254 patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors, the most used agents were dalpiciclib and abemaciclib. Over 81% experienced adverse events (AEs), with leukopenia and neutropenia being most common. Differences in safety and symptom burden among CDK4/6 inhibitors underscore the need for personalized treatment selection to optimize patient outcomes and well-being.
Today

The Central Drugs Standard Control Organisation has granted marketing authorization for Qdenga, marking India's first approved dengue vaccine. Developed by Takeda, this two-dose live-attenuated vaccine offers protection for individuals aged 4 to 60 without requiring prior serological screening.
Today

Johnson & Johnson announced a $5.5 billion settlement to resolve nearly 69,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. This comprehensive deal covers 99.75% of active claims. Read about the legal strategy, scientific evidence on talc exposure, and clinical counseling for patients.
Today

Researchers at SGPGIMS Lucknow have isolated and cultured human heart valve interstitial cells from donor tissues. This milestone advances understanding of rheumatic heart disease pathways like TGF-beta/SMAD3 and ERK1/2, laying the foundation for tissue-engineered heart valves and drug testing.
Today

Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
4 days back

Deepinder Goyal's healthtech startup Temple is raising capital at a $500 million valuation and pricing its temporal wearable at Rs 80,000. Worn on the side of the forehead, the device tracks microvascular blood flow and real-time Entropy to monitor physiological stress, metabolic expenditure, and recovery.
Today